Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

This study has been completed.
Information provided by:
Bader, Ted, M.D. Identifier:
First received: March 11, 2007
Last updated: September 8, 2008
Last verified: September 2008

Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.

Condition Intervention Phase
Hepatitis C
Drug: rosuvastatin
Drug: atorvastatin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

Resource links provided by NLM:

Further study details as provided by Bader, Ted, M.D.:

Estimated Enrollment: 16
Study Start Date: December 2006
Study Completion Date: March 2007

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hepatitis C

Exclusion Criteria:

  • HIV positivity
  Contacts and Locations
Please refer to this study by its identifier: NCT00446940

United States, Oklahoma
VA Hospital
OKlahoma City, Oklahoma, United States, 73104
Sponsors and Collaborators
Bader, Ted, M.D.
Principal Investigator: Ted Bader, MD VA Medical Center, Oklahoma City, OK
  More Information

No publications provided Identifier: NCT00446940     History of Changes
Other Study ID Numbers: 13133
Study First Received: March 11, 2007
Last Updated: September 8, 2008
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Enzyme Inhibitors
Lipid Regulating Agents
Therapeutic Uses processed this record on April 23, 2014